The ELISA-measured increase in cerebrospinal fluid tau that discriminates Alzheimer's disease from other neurodegenerative disorders is not attributable to differential recognition of tau assembly forms

Journal of Alzheimer's Disease

Volumn 33, Issue 4, 2013, Pages 923-928

  O'Dowd, Seán T ^a,b   Ardah, Mustafa T ^c   Johansson, Per ^d,e   Lomakin, Aleksey ^f   Benedek, George B ^f   Roberts, Kinley A ^b   Cummins, Gemma ^b   El Agnaf, Omar M ^c   Svensson, Johan ^e,g   Zetterberg, Henrik ^e   Lynch, Timothy ^b   Walsh, Dominic M ^a  

^a HARVARD INSTITUTES OF MEDICINE   (United States)

^b MATER MISERICORDIAE UNIVERSITY HOSPITAL   (Ireland)

^c UNITED ARAB EMIRATES UNIVERSITY   (United Arab Emirates)

^d SKARABORG HOSPITAL   (Sweden)

^e UNIVERSITY OF GOTHENBURG   (Sweden)

^f Massachusetts Institute of Technology Cambridge   (United States)

^g SKARABORG HOSPITAL   (Sweden)

Author keywords

Alzheimer's disease; cerebrospinal fluid; ELISA; tau

Indexed keywords

TAU PROTEIN;

ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; DEGENERATIVE DISEASE; ELISA KIT; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN ASSEMBLY;

EID: 84873645714     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2012-121393     Document Type: Article

References (27)

1. Blennow K, Hampel H,Weiner M, Zetterberg H (2010) Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 6, 131-144
2. Dubois B, Feldman HH, Jacova C, Dekosky ST, Barberger-Gateau P, Cummings J, Delacourte A, Galasko D, Gauthier S, Jicha G,Meguro K, O'brien J, Pasquier F, Robert P, Rossor M, Salloway S, Stern Y, Visser PJ, Scheltens P (2007) Research criteria for the diagnosis of Alzheimer's disease: Revising the NINCDS-ADRDA criteria. Lancet Neurol 6, 734-746
3. Grossman M, Farmer J, Leight S, Work M, Moore P, Van Deerlin V, Pratico D, Clark CM, Coslett HB, Chatterjee A, Gee J, Trojanowski JQ, Lee VM (2005) Cerebrospinal fluid profile in frontotemporal dementia and Alzheimer's disease. Ann Neurol 57, 721-729
4. Verwey NA, Kester MI, van der Flier WM, Veerhuis R, Berkhof H, TwaalfhovenH, Blankenstein MA, Scheltens And P, Pijnenburg YA (2010) Additional value of CSF amyloidbeta 40 levels in the differentiation between FTLD and control subjects. J Alzheimers Dis 20, 445-452
5. Bian H, Van Swieten JC, Leight S, Massimo L, Wood E, Forman M, Moore P, de Koning I, Clark CM, Rosso S, Trojanowski J, Lee VM, Grossman M (2008) CSF biomarkers in frontotemporal lobar degeneration with known pathology. Neurology 70, 1827-1835
6. Noguchi M, Yoshita M, Matsumoto Y, Ono K, Iwasa K, YamadaM(2005) Decreased beta-Amyloid peptide42 in cerebrospinal fluid of patients with progressive supranuclear palsy and corticobasal degeneration. J Neurol Sci 237, 61-65
7. Aerts MB, Esselink RA, Bloem BR, Verbeek MM (2011) Cerebrospinal fluid tau and phosphorylated tau protein are elevated in corticobasal syndrome. Mov Disord 26, 169-173
8. Urakami K, Wada K, Arai H, Sasaki H, Kanai M, Shoji M, Ishizu H, Kashihara K, Yamamoto M, Tsuchiya-Ikemoto K, Morimatsu M, Takashima H, Nakagawa M, Kurokawa K, Maruyama H, Kaseda Y, Nakamura S, Hasegawa K, Oono H, Hikasa C, Ikeda K, Yamagata K, Wakutani Y, Takeshima T, Nakashima K (2001) Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy. J Neurol Sci 183, 95-98
9. Borroni B, Gardoni F, Parnetti L, Magno L, Malinverno M, Saggese E, Calabresi P, Spillantini M, Padovani A, Di LucaM (2009) Pattern of Tau forms in CSF is altered in progressive supranuclear palsy. Neurobiol Aging 30, 34-40
10. Jack CJ, Knopman D, Jagust W, Shaw L, Aisen P, Weiner M, Petersen R, Trojanowski J (2010) Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 9, 119-128
11. Stenh C, Englund H, Lord A, Johansson AS, Almeida CG, Gellerfors P, Greengard P, Gouras GK, Lannfelt L, NilssonLN (2005) Amyloid-beta oligomers are inefficiently measured by enzyme-linked immunosorbent assay. Ann Neurol 58, 147-150
12. Tokuda T, Qureshi MM, Ardah MT, Varghese S, Shehab SA, Kasai T, Ishigami N, Tamaoka A, NakagawaM, El-AgnafOM (2010) Detection of elevated levels of -synuclein oligomers in CSF from patients with Parkinson disease. Neurology 75, 1766-1772
13. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E (1984) Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDAWork Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34, 939-944
14. Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55, 181-184
15. Neary D, Snowden JS, Gustafson L, Passant U, Stuss D, Black S, Freedman M, Kertesz A, Robert PH, Albert M, Boone K, Miller BL, Cummings J, Benson DF (1998) Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology 51, 1546-1554
16. Litvan I, Agid Y, Calne D, Campbell G, Dubois B, Duvoisin RC, Goetz CG, Golbe LI, Grafman J, Growdon JH, Hallett M, Jankovic J, Quinn NP, Tolosa E, Zee DS (1996) Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): Report of the NINDS-SPSP international workshop. Neurology 47, 1-9
17. Boeve BF, Lang AE, Litvan I (2003) Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol 54(SUPPL5), S15-S19
18. McKeith I, Dickson D, Lowe J, Emre M, O'Brien J, Feldman H, Cummings J, Duda J, Lippa C, Perry E, Aarsland D, Arai H, Ballard C, Boeve B, Burn D, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz C, Gomez-Tortosa E, Halliday G, Hansen L, Hardy J, Iwatsubo T, Kalaria R, Kaufer D, Kenny R, Korczyn A, Kosaka K, Lee V, Lees A, Litvan I, Londos E, Lopez O, Minoshima S, Mizuno Y, Molina J, Mukaetova-Ladinska E, Pasquier F, Perry R, Schulz J, Trojanowski J, Yamada M, DLB, Co (2005) Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium. Neurology 65, 1863-1872
19. Gilman S, Wenning GK, Low PA, Brooks DJ, Mathias CJ, Trojanowski JQ, Wood NW, Colosimo C, Dürr A, Fowler CJ, Kaufmann H, Klockgether T, Lees A, Poewe W, Quinn N, Revesz T, Robertson D, Sandroni P, Seppi K, Vidailhet M (2008) Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71, 670-676
20. Buchhave P, Minthon L, Zetterberg H, Wallin AK, Blennow K, Hansson O (2012) Cerebrospinal fluid levels of -Amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia. Arch Gen Psychiatry 69, 98-106
21. Barghorn S, Biernat J, Mandelkow E (2005) Purification of recombinant tau protein and preparation of Alzheimer-paired helical filaments in vitro. Methods Mol Biol 299, 35-51
22. Holtzman DM (2011) CSF biomarkers for Alzheimer's disease: Current utility and potential future use. Neurobiol Aging 32(SUPPL1), S4-S9
23. Parnetti L, Chiasserini D, Bellomo G, Giannandrea D, De Carlo C, Qureshi MM, Ardah MT, Varghese S, Bonanni L, Borroni B, Tambasco N, Eusebi P, Rossi A, Onofrj M, Padovani A, Calabresi P, El-Agnaf O (2011) Cerebrospinal fluid Tau/-synuclein ratio in Parkinson's disease and degenerative dementias. Mov Disord 26, 1428-1435
24. Harper JD, Lansbury PT (1997) Models of amyloid seeding in Alzheimer's disease and scrapie: Mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. Annu Rev Biochem 66, 385-407
25. van Harten AC, Kester MI, Visser PJ, Blankenstein MA, Pijnenburg YA, van der Flier WM, Scheltens P (2011) Tau and p-Tau as CSF biomarkers in dementia: A meta-Analysis. Clin Chem Lab Med 49, 353-366
26. Saman S, Kim W, Raya M, Visnick Y, Miro S, Jackson B, McKee AC, Alvarez VE, Lee NC, Hall GF (2012) Exosome-Associated tau is secreted in tauopathy models and is selectively phosphorylated in cerebrospinal fluid in early Alzheimer disease. J Biol Chem 287, 3842-3849
27. Chai X, Dage JL, Citron M (2012) Constitutive secretion of tau protein by an unconventional mechanism. Neurobiol Dis 48, 356-366